Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial.
Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D, Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB. Lopes RD, et al. Among authors: hochman js. Eur Heart J. 2009 Aug;30(16):2019-28. doi: 10.1093/eurheartj/ehp213. Epub 2009 Jun 6. Eur Heart J. 2009. PMID: 19502623 Free PMC article. Clinical Trial.
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW; COMMA Investigators. Granger CB, et al. Among authors: hochman js. Circulation. 2003 Sep 9;108(10):1184-90. doi: 10.1161/01.CIR.0000087447.12918.85. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925454 Clinical Trial.
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW; COMPLY Investigators. Mahaffey KW, et al. Among authors: hochman js. Circulation. 2003 Sep 9;108(10):1176-83. doi: 10.1161/01.CIR.0000087404.53661.F8. Epub 2003 Aug 18. Circulation. 2003. PMID: 12925455 Clinical Trial.
International variation in invasive care of the elderly with acute coronary syndromes.
Alexander KP, Newby LK, Bhapkar MV, White HD, Hochman JS, Pfisterer ME, Moliterno DJ, Peterson ED, Van de Werf F, Armstrong PW, Califf RM; Symphony and 2nd Symphony Investigators. Alexander KP, et al. Among authors: hochman js. Eur Heart J. 2006 Jul;27(13):1558-64. doi: 10.1093/eurheartj/ehl067. Epub 2006 Jun 7. Eur Heart J. 2006. PMID: 16760200
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.
van Diepen S, Roe MT, Lopes RD, Stebbins A, James S, Newby LK, Moliterno DJ, Neumann FJ, Ezekowitz JA, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Theroux P, Granger CB. van Diepen S, et al. Among authors: hochman js. J Thromb Thrombolysis. 2012 Jul;34(1):106-13. doi: 10.1007/s11239-012-0691-0. J Thromb Thrombolysis. 2012. PMID: 22307842 Clinical Trial.
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, Roe MT, Ezekowitz JA, Moliterno DJ, Neumann FJ, Reist C, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Granger CB, Theroux P; APEX AMI Investigators. van Diepen S, et al. Among authors: hochman js. Int J Cardiol. 2013 Oct 3;168(3):2127-33. doi: 10.1016/j.ijcard.2013.01.004. Epub 2013 Feb 8. Int J Cardiol. 2013. PMID: 23394896 Clinical Trial.
Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.
Bagai A, Armstrong PW, Stebbins A, Mahaffey KW, Hochman JS, Weaver WD, Patel MR, Granger CB, Lopes RD. Bagai A, et al. Among authors: hochman js. Am Heart J. 2013 Nov;166(5):913-9. doi: 10.1016/j.ahj.2013.08.006. Epub 2013 Sep 24. Am Heart J. 2013. PMID: 24176448 Clinical Trial.
469 results